Uniqure NV (NASDAQ:QURE) Director Paula Soteropoulos sold 9,082 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $64.26, for a total transaction of $583,609.32. Following the completion of the transaction, the director now directly owns 18,234 shares in the company, valued at $1,171,716.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Paula Soteropoulos also recently made the following trade(s):
- On Monday, December 9th, Paula Soteropoulos sold 2,500 shares of Uniqure stock. The stock was sold at an average price of $67.50, for a total transaction of $168,750.00.
QURE stock traded up $2.03 during trading on Tuesday, reaching $65.03. 38,932 shares of the stock were exchanged, compared to its average volume of 514,920. The company has a current ratio of 14.33, a quick ratio of 14.33 and a debt-to-equity ratio of 0.19. The business has a 50 day moving average price of $53.34 and a 200-day moving average price of $57.78. Uniqure NV has a 1 year low of $24.07 and a 1 year high of $82.49. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of -27.80 and a beta of 0.79.
A number of hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Uniqure by 21.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,975 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 346 shares during the period. Parametric Portfolio Associates LLC raised its stake in Uniqure by 8.4% during the second quarter. Parametric Portfolio Associates LLC now owns 4,835 shares of the biotechnology company’s stock worth $378,000 after purchasing an additional 376 shares during the period. US Bancorp DE raised its stake in Uniqure by 275.5% during the second quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 427 shares during the period. Griffin Asset Management Inc. acquired a new stake in shares of Uniqure during the second quarter valued at about $39,000. Finally, Royal Bank of Canada increased its position in shares of Uniqure by 9.7% during the second quarter. Royal Bank of Canada now owns 6,075 shares of the biotechnology company’s stock valued at $474,000 after acquiring an additional 536 shares during the last quarter. 73.13% of the stock is currently owned by institutional investors.
Several equities analysts have recently weighed in on the stock. Mizuho reissued a “buy” rating and issued a $90.00 price target (up from $67.00) on shares of Uniqure in a research note on Tuesday. Stifel Nicolaus assumed coverage on shares of Uniqure in a research note on Friday, October 11th. They issued a “buy” rating and a $79.00 price target on the stock. Cowen assumed coverage on shares of Uniqure in a research note on Tuesday, December 3rd. They issued an “outperform” rating on the stock. BidaskClub raised shares of Uniqure from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Finally, Goldman Sachs Group assumed coverage on shares of Uniqure in a research note on Tuesday, December 3rd. They issued a “buy” rating and a $98.00 price target on the stock. Two research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Uniqure presently has a consensus rating of “Buy” and an average target price of $79.20.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Featured Story: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.